{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:28Z","timestamp":1792511968337,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40265-021-01599-7","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T15:03:07Z","timestamp":1631631787000},"page":"1787-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Finerenone: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"1599_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa294","author":"R Agarwal","year":"2020","unstructured":"Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2020. https:\/\/doi.org\/10.1093\/ndt\/gfaa294.","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"1599_CR2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"1599_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ejhf.444","volume":"18","author":"P Bramlage","year":"2016","unstructured":"Bramlage P, Swift SL, Thoenes M, et al. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18(1):28\u201337.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1599_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","volume":"33","author":"I Capelli","year":"2020","unstructured":"Capelli I, Gasperoni L, Ruggeri M, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol. 2020;33(1):37\u201348.","journal-title":"J Nephrol"},{"key":"1599_CR5","unstructured":"US Food & Drug Administration. FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes [media release]. 9 Jul 2021. https:\/\/www.fda.gov\/drugs."},{"key":"1599_CR6","unstructured":"Bayer HealthCare Pharmaceuticals Inc. KERENDIA (finerenone) tablets, for oral use: US prescribing information. 2021. https:\/\/labeling.bayerhealthcare.com. Accessed 13 Jul 2021."},{"key":"1599_CR7","unstructured":"Bayer Healthcare Pharmaceuticals. Bayer submits regulatory applications for investigational drug finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes [media release]. 9 Nov 2020. http:\/\/www.bayer.us."},{"key":"1599_CR8","unstructured":"Bayer Healthcare Pharmaceuticals. Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes [media release]. 9 Feb 2021. http:\/\/www.bayer.com."},{"key":"1599_CR9","unstructured":"Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine. 2021. https:\/\/patents.google.com\/patent\/WO2020178175A1\/en. Accessed 12 Jul 2021."},{"issue":"8","key":"1599_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L Barfacker","year":"2012","unstructured":"Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403.","journal-title":"ChemMedChem"},{"key":"1599_CR11","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932\u201340.","journal-title":"J Biol Chem"},{"issue":"6","key":"1599_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","volume":"14","author":"B Pitt","year":"2012","unstructured":"Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14(6):668\u201375.","journal-title":"Eur J Heart Fail"},{"key":"1599_CR13","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1021\/jm1002827","volume":"53","author":"GB Arhancet","year":"2010","unstructured":"Arhancet GB, Woodard SS, Dietz JD, et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem. 2010;53:4300\u20134.","journal-title":"J Med Chem"},{"key":"1599_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","volume":"51","author":"JD Dietz","year":"2008","unstructured":"Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008;51:742\u20138.","journal-title":"Hypertension"},{"key":"1599_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, et al. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1599_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","volume":"67","author":"A Gueret","year":"2016","unstructured":"Gueret A, Harouki N, Favre J, et al. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension. 2016;67(4):717\u201323.","journal-title":"Hypertension"},{"key":"1599_CR17","doi-asserted-by":"crossref","unstructured":"Dutzmann J, Musmann RJ, Haertl\u00e9 M, et al. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE. 2017;12(9):e0184888.","DOI":"10.1371\/journal.pone.0184888"},{"key":"1599_CR18","doi-asserted-by":"crossref","unstructured":"Barrera-Chimal J, Andr\u00e9-Gr\u00e9goire G, Nguyen Dinh Cat A, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol. 2017;28(4):1216-26.","DOI":"10.1681\/ASN.2016040477"},{"issue":"5","key":"1599_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69(5):870\u20138.","journal-title":"Hypertension"},{"issue":"6","key":"1599_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93(6):1344\u201355.","journal-title":"Kidney Int"},{"key":"1599_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","volume":"121","author":"B Bonnard","year":"2018","unstructured":"Bonnard B, Pieronne-Deperrois M, Djerada Z, et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 2018;121:124\u201333.","journal-title":"J Mol Cell Cardiol"},{"key":"1599_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez R, Somoza B, Gil-Ortega M, et al. Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol. 2018;9:1131.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1599_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000506275","volume":"51","author":"M Gil-Ortega","year":"2020","unstructured":"Gil-Ortega M, Vega-Mart\u00edn E, Mart\u00edn-Ramos M, et al. Finerenone reduces intrinsic arterial stiffness in Munich Wistar Fr\u00f6mter rats, a genetic model of chronic kidney disease. Am J Nephrol. 2020;51(4):294\u2013303.","journal-title":"Am J Nephrol"},{"key":"1599_CR24","unstructured":"Hirohama D, Nishimoto M, Ayuzawa N, et al. The mineralocorticoid receptor antagonist finerenone limits podocyte injury in high-salt loaded db\/db mice [abstract no. FR-PO207]. J Am Soc Nephrol. 2019;30:487."},{"key":"1599_CR25","doi-asserted-by":"crossref","unstructured":"Droebner K, Pavkovic M, Grundmann M, et al. The novel nonsteroidal and selective mineralocorticoid receptor antagonist finerenone differentiates from SGLT2 inhibitor empagliflozin by anti-fibrotic effects in a progressive mouse kidney fibrosis model [abstract no. PO0646]. J Am Soc Nephrol. 2020;31:244.","DOI":"10.1681\/ASN.20203110S1244d"},{"issue":"4","key":"1599_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"issue":"1","key":"1599_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"1599_CR28","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/ehf2.13219","volume":"8","author":"M Pieronne-Deperrois","year":"2021","unstructured":"Pieronne-Deperrois M, Gu\u00e9ret A, Djerada Z, et al. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail. 2021;8(3):1933\u201343.","journal-title":"ESC Heart Fail."},{"key":"1599_CR29","first-page":"846","volume":"30","author":"F Jaisser","year":"2019","unstructured":"Jaisser F, Pieronne-Deperrois M, Bonnard B, et al. Finerenone improves cardiovascular benefits after diet normalization in a mouse model of high-fat diet-induced obesity [abstract no. SA-PO322]. J Am Soc Nephrol. 2019;30:846\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1599_CR30","doi-asserted-by":"publisher","DOI":"10.1159\/000516213","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021. https:\/\/doi.org\/10.1159\/000516213.","journal-title":"Am J Nephrol"},{"issue":"2","key":"1599_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, et al. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"1599_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","volume":"43","author":"R Heinig","year":"2018","unstructured":"Heinig R, Gerisch M, Engelen A, et al. Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"1599_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, et al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1599_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1599_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, et al. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1599_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, et al. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44(5):619\u201328.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1599_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","volume":"45","author":"R Heinig","year":"2020","unstructured":"Heinig R, Gerisch M, Bairlein M, et al. Results from drug-drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet. 2020;45(4):433\u201344.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"1599_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"issue":"5","key":"1599_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):345\u201356.","journal-title":"Am J Nephrol"},{"key":"1599_CR40","unstructured":"Bayer HealthCare Pharmaceuticals. Bayers finerenone meets primary endpoint in phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes [media release]. 10 May 2021. www.bayer.com."},{"issue":"31","key":"1599_CR41","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"6","key":"1599_CR42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000371497","volume":"40","author":"LM Ruilope","year":"2014","unstructured":"Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6):572\u201381.","journal-title":"Am J Nephrol"},{"issue":"9","key":"1599_CR43","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"4","key":"1599_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4):758\u201365.","journal-title":"J Diabetes Complications"},{"key":"1599_CR45","doi-asserted-by":"crossref","unstructured":"Pitt B, Anker SD, B\u00f6hm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-32.","DOI":"10.1002\/ejhf.218"},{"key":"1599_CR46","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14.","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"1599_CR47","doi-asserted-by":"crossref","unstructured":"Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease. Circ J. 2016;80(5):1113-22.","DOI":"10.1253\/circj.CJ-16-0122"},{"key":"1599_CR48","unstructured":"Bayer Healthcare Pharmaceuticals. Bayer extends clinical development program for finerenone with phase III study in patients with heart failure and preserved ejection fraction [media release]. 15 Jun 2021. http:\/\/www.bayer.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01599-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T10:03:25Z","timestamp":1725789805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01599-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":48,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01599-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"14 September 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. James E. Frampton is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}